OAMRS 2026 Fall Nuclear Medicine Symposium

November 21, 2026 6.0 CE hours 9:00 AM – 3:00 PM ET

Hosted by OAMRS

Registration and event changes are handled on oamrs.org. Everything you register for is reflected in your member record.

About this event

This year’s event will feature highly knowledgeable and expert presenters discussing topics related to nuclear medicine. You won't want to miss this opportunity to hear the latest on topics ranging from imaging for cancer treatment and more.

Program accreditation with ASRT has been applied for. Participants who attend this program will receive a certificate of attendance from OAMRS containing 6.0 continuing education hours and 6.0 ASRT Category A approved credits. This program and associated credits are recognized by ARDMS.

*Please note that virtual program fees are non-refundable

*Please note full attendance to this event is required to receive CME and ASRT credits.

What Your Colleagues Have Said About Our Nuclear Medicine Symposiums:

“The OAMRS always puts on great symposiums! Their speakers are full of informative and interesting information. The audio and video feeds are always top-notch! I would recommend these webinars to everyone!”
—C., The Dalles, OR

“FINALLY! Presentations about Nuclear Medicine, Theranostics and molecular imaging. It's not often in these conferences/webinars that the focus is on these topics. Thank you!”
—Attendee

“I am always impressed by the quality of the continuing education provided by OAMRS. The low fees for OAMRS members makes the cost of membership well worthwhile."
—H., Kitchener, ON

Programme

9 entries

8:55 AM
Welcome and Opening Remarks - Ontario Association of Medical Radiation Sciences
9:00 AM
Clinical production of radiopharmaceuticals: The London
Experience

Michael Kovacs, Ph.D., Imaging Program Leader, Lawson Research Institute
Dr. Michael Kovacs is a radiochemist, imaging scientist, and Director of the Lawson Cyclotron and Radiochemistry Facility in London, Ontario. His research focuses on developing new radiopharmaceuticals and molecular imaging tools that help visualize disease and guide precision therapies. Over the past two decades, he has worked at the intersection of chemistry, engineering, and clinical imaging, leading projects ranging from novel PET tracers to medical isotope production and image-guided therapeutics. As Program Leader of the Lawson Imaging Research Program and an Assistant Professor at Western University, Dr. Kovacs works closely with clinicians, scientists, technologists, and trainees to translate innovative imaging technologies into patient care.
Presentation Objectives:
- Describe the key infrastructure, personnel, regulatory, and quality assurance requirements necessary to establish and operate a clinical cyclotron and GMP-compliant radiopharmaceutical production facility.
- Explain the process of translating novel PET radiotracers and theranostic agents from research to clinical implementation, including radiochemistry, production workflows, quality control, and regulatory considerations.
- Evaluate operational and business factors that influence the sustainability of radiopharmaceutical production programs, including equipment reliability, staffing, supply chains, and cost-recovery models.
- Discuss the principles underlying theranostic radiopharmaceutical pair selection, with examples such as PSMA-targeted imaging and therapy agents, and understand how radionuclide characteristics impact clinical applications.
- Identify emerging opportunities and challenges in radiotheranostics, including cyclotron-produced isotopes, novel molecular targets, isotope supply considerations, and the evolving role of theranostics in precision medicine.
1.0 CE Hour
10:00 AM
Theranostics Overview
Dr. Patrick Veit-Haibach, MD, UHN, JDMI

Patrick Veit-Haibach is a dual-certified Radiologist and Nuclear Medicine Physician at the Joint Department Medical Imaging, Toronto. He spend his residency and initial staff years in Germany and in Switzerland at the University Hospital Zurich and the Cantonal Hospital Lucerne. Dr. Veit-Haibach joined the JDMI in Toronto in April 2017 as the Director of PET/MR program. Since then, he assumed the position of the Division Head Abdominal Imaging in JDMI as well as Deputy Radiologistin-Chief and Program Medical Director and currently serves as the Managing Director of Neuroradiology. In addition, he has been appointed as the Theranostic Lead at JDMI as serves as the Co-Director of the Silber Family Theranostic Centre at UHN. Dr. Veit-Haibach is Full Professor for Radiology and Nuclear Medicine at the University of Toronto.
Presentation Objectives:
- Understand the basics of theranostics
- Learn about the how theranostics is currently done in clinical routine
- Understand the current clinical indications specifically in NET and prostate cancer.
- The talks will also give an overview on how PET-imaging and SPECT imaging is currently used for staging, therapy qualification and follow up.
1.0 CE Hour
11:00 AM
Morning Break
11:15 AM
Advocating for a Nuclear Medicine Strategy in Ontario
More PETs Coalition
The More PETs Coalition is a group of organizations and individuals, including doctors, patients, disease-focused charities, and radiopharmaceutical providers, who share the goal of ensuring that PET scans are used to their full potential in the Ontario healthcare system.
Presentation Objectives:
- Representatives from the More PETs Coalition will introduce the Coalition, its goals, and its advocacy and awareness work. The Coalition is currently advocating for a modernized, strategic approach to nuclear medicine and PET scan delivery in Ontario, one that addresses existing barriers such as infrastructure, PET utilization, and health human resources.
1.0 CE Hour
12:15 PM
Lunch Break
12:45 PM
Computational Oncology, Virtual Clinical Trials, and Digital Twinning of Cancer Patients for Precision Therapies
Dr. Arman Rahmim, PhD, DABSNM, FSNMMI, Canada Research Chair in Theranostics and AI, Professor of Radiology, Physics, and Biomedical Engineering at the University of British Columbia, and Distinguished Scientist at the BC Cancer Research Institute
Dr. Arman Rahmim is Canada Research Chair in Theranostics and AI, and Professor of Radiology, Physics, and Biomedical Engineering at the University of British Columbia, as well as Distinguished Scientist at the BC Cancer Research Institute. After 13 years on the faculty at Johns Hopkins University, he returned to Vancouver in 2018 to lead the Quantitative Radiomolecular Imaging & Therapy (Qurit) Lab. He has authored a book, published more than 360 journal articles, and delivered over 220 invited lectures worldwide. He also hosts the Molecular Imaging & Therapy YouTube channel and serves as Co-Founder and Chief Scientific Officer of Ascinta Technologies. Dr. Rahmim was awarded in 2022 the Presidential Distinguished Service Award by the Society of Nuclear Medicine & Molecular Imaging (SNMMI) for significant contributions to the field of nuclear medicine & molecular imaging, and in 2025 the SNMMI Edward Hoffman Memorial Award for outstanding contributions to computational nuclear medicine research, best-practice, training and education. He served as Founding Chair of the SNMMI AI Task Force (2020–2024) and continues to lead the Computational Nuclear Oncology Working Group.
Presentation Objectives:
- Explain the role of computational oncology, including Computational Nuclear Oncology (CNO), in integrating quantitative imaging, mathematical modeling, and biological mechanisms to advance precision cancer care and theranostics.
- Describe how virtual clinical trials and computational simulations can support the evaluation and optimization of cancer imaging and treatment strategies, including radiopharmaceutical therapies.
- Discuss the potential of patient-specific digital twins to predict treatment response, personalize theranostic and other cancer therapies, and support clinical decision-making.
1:45 PM
Everything Old is New Again – The New Paradigm for Radiopharmaceutical Therapy in Pediatric Thyroid Cancer
Dr. Helen Nadel, MD, FRCPC, FSNMMI, Pediatric Radiologist and Nuclear Medicine Physician, Director of Nuclear Medicine, Department of Radiology, Lucile Packard Children's Hospital at Stanford University
Dr. Nadel is a dual board-certified Pediatric Radiologist and Nuclear Medicine Physician in both the USA and Canada. She holds certifications from the Royal College of Physicians and Surgeons of Canada in Diagnostic Radiology and Nuclear Medicine, The American Board of Radiology (ABR) with certificate of added qualification in Pediatric Radiology and the American Board of Nuclear Medicine (ABNM). She has been working with the entire breadth of general and hybrid nuclear medicine studies in children in a fully integrated department of Pediatric Radiology and lecturing to promote this field for her entire career. Dr. Nadel started the pediatric PET CT program in British Columbia in 2007. Dr. Nadel currently uses PET/MRI exclusively for PET imaging at Lucile Packard Children’s Hospital at Stanford University since joining the Pediatric Radiology Department as Director of Pediatric Nuclear Medicine in 2018. She is a Past President of the Society of Nuclear Medicine and Molecular Imaging.
Presentation Objectives:
- Describe the change in paradigm for imaging and treatment of children with thyroid cancer
- Identify potential for theranostics in children
1.0 CE Hour
2:45 PM
Concluding Remarks - Ontario Association of Medical Radiation Sciences

Schedule, speakers and biographies as published on oamrs.org. Times are Eastern.